EV71 vaccine, an invaluable gift for children

Clinical and Translational Immunology

Volumn 3, Issue 10, 2014, Pages

  Liang, Zhenglun ^a   Wang, Junzhi ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937452946     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2014.24     Document Type: Review

References (22)

1. A Guide to clinical management and public health response for hand, foot and mouth disease (HFMD) 2011. Available from http://www.wpro.who.int/emerging_diseases/documents/HFMDGuidance/en/.
2. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT et al. Hand, foot and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis 2014; 14: 308–318.
3. Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X et al. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 2013; 9: 1701–1705.
4. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X et al. Efficacy, safety and immunogenicity of an enterovirus 71 vaccine in China. New Engl J Med 2014; 370: 818–828.
5. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H et al. Efficacy, safety and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381: 2024–2032.
6. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z et al. An inactivated enterovirus 71 vaccine in healthy children. New Engl J Med 2014; 370: 829–837.
7. Mao Q, Li N, Yu X, Yao X, Li F, Lu F et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 2012; 157: 37–41.
8. Liang ZL, Mao Q, Gao F, Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2013; 7: 111–121.
9. Liang ZL, Mao QY, Gao Q, Li X, Dong C, Yu X et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29: 9668–9674.
10. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012; 30: 3295–3303.
11. Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF et al. Immunogenicity, safety and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled Trial. J Infect Dis 2014; 209: 46–55.
12. Meng FY, Li JX, Li XL, Chu K, Zhang YT, Ji H et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012; 8: 668–674.
13. Zhu FC, Liang ZL, Li XL, GE HM, Meng FY, Mao QY et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381: 1037–1045.
14. Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS ONE 2013; 8: e54451.
15. Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, Chang L et al. Immunogenicity, safety and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013; 20: 1805–1811.
16. Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 2010; 28: 3516–3521.
17. Cai Y, Ku Z, Liu Q, Leng Q, Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014; 32: 2406–2412.
18. Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children. PLoS ONE 2013; 8: e79599.
19. Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE 2013; 8: e79783.
20. Lee BY, Wateska AR, Bailey RR, Tai JH, Bacon KM, Smith KJ et al. Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine 2010; 28: 7731–7736.
21. Chen CW, Lee YP, Wang YF, Yu CK. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011; 29: 2772–2776.
22. McMinn PC. Enterovirus vaccines for an emerging cause of brain-stem encephalitis. New Engl J Med 2014; 370: 792–794.